In our study, we analyzed the impact of TP53 mutation on overall survival (Figure 1) using data from The Cancer Genome Atlas (TCGA) for 12 major TCGA cancers: bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma (PAAD), sarcoma (SARC), stomach cancer (STAD), and uterine corpus endometrial carcinoma (UCEC). Here, TP53 is linked to cancer.